gp100 (25 33), human

Gp100 (25-33), human is the amino acids 25-33 fragment of the human melanoma antigen. It is a 9-amino acid (AA) epitope restricted by H-2Db and recognized by the T cells.This is amino acids 25 to 33 fragment of human melanoma antigen gp100. This H-2Db res

Gp100 (25-33), human TFA is a 25-33 amino acid fragment of human melanoma antigen.Gp100 (25-33), human TFA is a 9-amino acid (AA) epitopes restricted by h-2db and recognized by T cells.

RFRP-1 (human) acetate is a potent endogenous NPFF receptor agonist (EC50 values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes. Reduces heart rate, stroke volume, eject

GLP-2(1-33) (human) is an enteroendocrine hormone which stimulates the growth of the intestinal epithelium.

GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM. GP33-41 Epitopeis a strong agonist of CD8 T cells

Gp100 (25-33) corresponds to residues 25 to 33 of the mouse self/tumor antigen glycoprotein (mgp100), which is an enzyme responsible for pigment synthesis. This epitope fragment is found in both normal melanocytes and melanoma cells.

CRF(6-33)(human) is a Corticotropin-releasing factor binding protein (CRFBP) inhibitor peptide; displaces CRF from CRFBP. Suppresses body weight gain and increases motor activity in obese rats in vivo.

[Thr28, Nle31]-Cholecystokinin (25-33) is a bioactive peptide analog of Cholecystokinin (CCK), functioning as both a hormone and neurotransmitter within the gastrointestinal system and central nervous system, with a role in satiation by inhibiting food intake. Compared to native CCK8, this analog displays enhanced stability in acidic environments and resistance to air oxidation, attributed to the substitution of Methionine with Threonine at position 28 and Norleucine at position 31. Structurally, its predominant feature is a gamma-turn at Thr4, followed by a Gly5-separated helical region encompassing the C-terminal residues.

Amyloid-β (25-35) (Aβ (25-35)) is an 11-residue fragment of the Aβ protein that retains the physical and biological characteristics of the full length peptide. It forms fibrils that react to thioflavin T and Congo red and are organized in a cross-β arrangement of β-strands similar to Aβ (1-40) and Aβ (1-42) fibrils. Aggregated Aβ (25-35) decreases the viability of rat adrenal PC12 cells. It also decreases the viability of primary rat cortical neurons at concentrations ranging from 1 nM to 30 μM. In vivo, intracerebral injection of Aβ (25-35) (20 nmol) in rats induces lesions of neuronal and tissue loss. Aggregated Aβ (25-35) administered intracerebroventricularly to rats induces learning and memory impairments in the Y-maze, novel object recognition, and contextual fear conditioning tests.

Hepcidin-25 (human) acetate is a modulator of iron metabolism that demonstrates anti-inflammatory and antibacterial effects through the modulation of iron-mediated oxidant injury [1].

GP(33-41) TFA, a 9-amino-acid (aa) peptide, represents the optimal sequence of the lymphocytic choriomeningitis virus GP1 epitope, effectively upregulating H-2D b molecules on the RMA-S (Db Kb) cell surface with a SC 50 value of 344 nM [1].

Hepcidin-25 (human), an iron metabolism modulator, exhibits both anti-inflammatory and antibacterial activity through the modulation of iron-mediated oxidant injury [1].

Neuromedin U (NMU) is a neuropeptide first demonstrated to drive smooth muscle contraction.1Translated as a 174 amino acid propeptide, NMU is cleaved to different lengths in different animals. It has diverse receptor-mediated rolesin vivo, as it regulates feeding, vasoconstriction, nociception, and bone remodeling and contributes to obesity, cancer and septic shock.2,2NMU-25 is the active form of NMU in humans. It binds with high affinity to receptors on human left ventricle and coronary artery (KDs = 0.26 and 0.11 nM, respectively), eliciting endothelium-independent vasoconstriction.3NMU-25 also suppresses glucose-stimulated insulin secretion in human islets, and this effect is lost in NMU R165W mutants, resulting in early-onset obesity.4 1.Mitchell, J.D., Maguire, J.J., and Davenport, A.P.Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin SBritish Journal of Pharmacology15887-103(2009) 2.Greenwood, H.C., Bloom, S.R., and Murphy, K.G.Peptides and their potential role in the treatment of diabetes and obesityRev.Diabet.Stud.8(3)355-368(2011) 3.Mitchell, J.D., Maguire, J.J., Kuc, R.E., et al.Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular systemCardiovascular Research81353-361(2009) 4.Alfa, R.W., Park, S., Skelly, K.R., et al.Suppression of insulin production and secretion by a decretin hormoneCell Metabolism21(2)323-333(2015)

Agouti-related peptide (AgRP) is a neuropeptide produced in the brain by the AgRP/NPY neuron. It is only synthesized in NPY containing cell bodies located in the ventromedial part of the arcuate nucleus in the hypothalamus. The appetite-stimulating effect

CRF(6-33)(human) TFA acts as a competitive inhibitor of the Corticotropin-Releasing Factor Binding Protein (CRF-BP), selectively interacting with CRF-BP without affecting post-synaptic Corticotropin-Releasing Factor receptors. This compound demonstrates an anti-obesity effect, as evidenced by studies [1] [2].

Gonadotropin-Releasing Hormone-Associated Peptide (GAP) (25-53), Human, also known as hGAP-25-53, is a fragment of the human gonadotropin-releasing hormone-associated peptide that serves as an immunogen for producing antiseras such as MC-1, MC-2, and MC-3. This peptide is connected to the luteinizing hormone-releasing hormone (LH-RH) sequence through a 3 amino acid processing site [1].